Clinical trialNCT00387465CompletedPhase 1/PHASE2Interventional

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

SponsorNational Cancer Institute (NCI)Enrollment94Recurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial is studying the side effects and best dose of azacitidine when given together with entinostat and to see how well they work in treating patients with recurrent advanced non-small cell lung cancer. Azacitidine and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with entinostat may kill more tumor cells.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

John Wrangle
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
Sidney Kimmel Cancer Center
San Diego, California, United States
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Johns Hopkins University/sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Baltimore, Maryland, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →Entinostat

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2006
Primary completion: 31 May 2014
Completion: 30 Nov 2014
Last update posted: 9 May 2019
Registered enrollment: 94
Registry id: NCT00387465

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.